Compare Rex Fang & Innovation Equity Premium Income ETF (FEPI) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rex Fang & Innovation Equity Premium Income ETF vs State Street SPDR S&P Biotech ETF — how do they compare? Rex Fang & Innovation Equity Premium Income ETF trades at $43.51 (market cap $746.48M), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 13.5× Rex Fang & Innovation Equity Premium Income ETF's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Rex Fang & Innovation Equity Premium Income ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Rex Fang & Innovation Equity Premium Income ETF for 56 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| FEPI | XBI | |
|---|---|---|
Market Cap | $746.48M | $10.11B |
Volume | 334,337 | 12,903,266 |
Sector | Income / Options Overlay | Broad Market / Factor |
52-Week High | $49.54 | $169.55 |
52-Week Low | $37.98 | $104.99 |
Typical Hold Time | 56 Days | 38 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FEPI (REX FANG & Innovation Equity Premium Income ETF) trades at $43.18, down 0.94% with a bullish technical signal from moving averages. The ETF employs a covered call strategy on AI and mega-cap tech stocks, generating substantial weekly dividends averaging $0.20-0.21 per share. Technical indicators show support at $43 and resistance at $44, with RSI suggesting potential overbought conditions. Recent news highlights FEPI's 25% yield but notes underperformance versus peers in total returns.
The outlook remains income-focused with high yield appeal, though capped upside and concentrated tech exposure present risks. Elevated volatility in AI sectors could impact distributions, while competitive covered call ETFs offer alternatives. Investors should weigh income stability against total return potential and sector concentration risks in the current market environment.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Rex Fang & Innovation Equity Premium Income ETF
FEPI provides exposure to top innovation stocks while generating monthly income. It uses a covered call strategy on high-volatility tech stocks to capture option premiums for investors.
Read more on FEPI →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
